Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Deberardino

Sports Medicine San Antonio, TX Medical Doctor

NPI 1033191176 CMS profile 137782

8300 Floyd Curl Dr Fl 3, San Antonio, TX 78229

Open in the dashboard

General payments

$3,515,893

812 records reported · program years 2019–2025

Research payments

$20,700

Paid to them · 9 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$23,041 paid to institutions, not to them · program year 2025

Through program year 2025, Thomas Deberardino of San Antonio, TX is reported in the CMS Open Payments database as having received $3,515,893 across 812 general payments and $20,700 in research payments paid to them. Separately, studies naming them as principal investigator received $23,041 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $452,857 61
2024 General $669,090 103
2023 General $766,189 98
2023 Research $5,400 2
2022 General $614,036 108
2022 Research $4,950 2
2021 General $506,661 161
2021 Research $4,500 2
2020 General $238,755 85
2020 Research $4,050 2
2019 General $268,305 196
2019 Research $1,800 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Deberardino
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Thomas Deberardino were reported at $452,857. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Thomas Deberardino Sports Medicine median Middle half National median
2019 $268,305 $1,176 $199–$4,249 $163
2020 $238,755 $708 $96–$2,890 $114
2021 $506,661 $1,213 $152–$3,994 $132
2022 $614,036 $1,230 $159–$3,998 $149
2023 $766,189 $584 $146–$2,836 $160
2024 $669,090 $628 $163–$3,168 $164
2025 $452,857 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $3,507,352 739 payments
  2. NovoPedics, Inc. $2,907 3 payments
  3. Kowa Pharmaceuticals America, Inc. $1,740 1 payment
  4. Medinc of Texas $397 7 payments
  5. Vericel Corporation $397 4 payments
  6. Mission Medical Distribution, LLC $394 5 payments
  7. Moximed, Inc $378 6 payments
  8. Djo, LLC $335 3 payments
  9. Pacira Pharmaceuticals Incorporated $300 5 payments
  10. Musculoskeletal Transplant Foundation Inc. $249 2 payments
  11. Other $1,443 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $2,368,260 28 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $963,225 141 payments
  3. Consulting Fee $104,990 49 payments
  4. Travel and Lodging $65,514 182 payments
  5. Food and Beverage $12,253 410 payments
  6. Honoraria $1,650 2 payments
Products named General payments · program years 2019–2025
  1. Arthrex Knee & Hip - Implants - Suspensory Fixation - Quad Tendon ACL TRI $1,140,670 8 payments
  2. Arthrex Knee & Hip - Implants - Suspensory Fixation - Quad Tendon ACL TRI $1,140,670 8 payments
  3. Arthrex Knee & Hip - Implants - Suspensory Fixation - Quad Tendon ACL TRI $1,140,670 8 payments
  4. Arthrex Knee & Hip - Implants - Suspensory Fixation - Quad Tendon ACL TRI $1,140,670 8 payments
  5. Arthrex Knee & Hip - Implants - Suspensory Fixation - Quad Tendon ACL TRI $1,035,281 7 payments
  6. Arthrex Knee & Hip - Implants - Suspensory Fixation - Quad Tendon ACL TRI - QuadLink Kit $809,560 9 payments
  7. ARTHREX Knee & Hip - Implants - Suspensory Fixation - Acl Tightrope $727,620 8 payments
  8. ARTHREX Knee & Hip - Implants - Suspensory Fixation - Acl Tightrope $727,620 8 payments
  9. ARTHREX Knee & Hip - Implants - Suspensory Fixation - Acl Tightrope $555,099 5 payments
  10. ARTHREX Knee & Hip - Implants - Suspensory Fixation - Acl Tightrope $483,364 4 payments
  11. Other $2,773,523 114 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Aesculap Biologics, LLC $20,700 9 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

60

Median for Sports Medicine: 144

Drug cost

$346

Median for Sports Medicine: $1,027

Branded share of claims

0%

Median for Sports Medicine: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone Hcl Generic 60 $346

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,691 Part D prescribers listed as Sports Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$40,531

Of which drugs: $4,957

Medicare patients

126

Average age 72

Services billed

8,208

79 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 69%
Diabetes 36%
Depression 23%
Ischemic heart disease 21%
Chronic kidney disease 20%
Osteoporosis 15%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

821 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record